Table 5. Antidepressant use among women with invasive breast cancer, by ER status, and controls.

	ER+ cases	ER– cases	Controls	ER+ compared to controlsa		ER− compared to controlsa
Exposure variables	n	n	n	OR	95% CI	OR	95% CI
No antidepressants	1307	325	10970	1.00		1.00
Antidepressant
Any use	457	106	3426	1.05	0.93–1.19	1.01	0.79–1.30
2–10 prescriptions	207	45	1503	1.09	0.92–1.29	0.93	0.65–1.33
11–20 prescriptions	95	16	627	1.19	0.94–1.51	0.87	0.50–1.50
21–50 prescriptions	84	25	760	0.85	0.67–1.10	1.05	0.66–1.65
51+ prescriptions	71	20	536	1.04	0.79–1.36	1.39	0.86–2.26
Tricyclic
Any use	386	84	2850	1.07	0.94–1.21	0.95	0.72–1.24
2–10 prescriptions	200	48	1484	0.97	0.68–1.38	1.06	0.90–1.26
11–20 prescriptions	74	12	490	0.92	0.51–1.66	1.19	0.92–1.55
21–50 prescriptions	67	10	557	0.55	0.27–1.13	0.94	0.72–1.25
51+ prescriptions	45	14	319	1.63	0.91–2.90	1.09	0.77–1.60
SSRI
Any use	108	28	911	0.93	0.74–1.16	1.05	0.69–1.60
2–10 prescriptions	55	13	461	0.92	0.68–1.24	1.05	0.59–1.87
11–20 prescriptions	26	7	203	0.95	0.61–1.47	0.87	0.35–2.15
21+ prescriptions	27	8	247	0.93	0.62–1.41	1.21	0.58–2.51
Atypical
Any use	108	31	876	0.92	0.73–1.16	1.15	0.76–1.74
2–10 prescriptions	66	19	535	0.93	0.70–1.23	1.11	0.66–1.86
11–20 prescriptions	17	6	135	1.06	0.62–1.80	1.76	0.76–4.07
21+ prescriptions	25	6	206	0.82	0.52–1.31	0.89	0.36–2.20
Amitriptyline
Any use	186	38	1191	1.22	1.02–1.45	1.09	0.75–1.58
2–10 prescriptions	113	23	756	1.19	0.95–1.48	1.05	0.66–1.67
11+ prescriptions	73	15	435	1.27	0.96–1.66	1.16	0.65–2.06

^aAdjusted for age, length of enrollment, calendar year, family history of breast cancer, parity/age at first birth, duration of HRT use, body mass index, and history of screening mammogram in 2 years prior to reference date.